{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-047206","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.075834+00:00","generated_at":"2026-05-24T01:48:43.523870+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Palvella Therapeutics reports FY2024 net loss $17.4M, cash $83.6M; SELVA top-line Q1 2026 on track","bullets":["Net loss $17.4M ($7.83/share) vs net income $17.9M in FY2023; R&D expense $8.2M, G&A $5.9M.","Cash and equivalents $83.6M, expected to fund operations into H2 2027.","Completed merger and $78.9M private placement in Dec 2024 with BVF, Frazier Life Sciences.","Phase 3 SELVA top-line Q1 2026; Phase 2 TOIVA top-line Q4 2025; both for QTORIN rapamycin.","Plans to expand QTORIN pipeline with new indication and product candidate in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-047206","json":"https://secwatch.observer/filing/0000950170-25-047206.json","markdown":"https://secwatch.observer/filing/0000950170-25-047206.md","text":"https://secwatch.observer/filing/0000950170-25-047206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/0000950170-25-047206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/pvla-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:48:43.523870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}